César de la Fuente is on a mission to combat antimicrobial resistance by looking at nature's own solutions. César de la Fuente is an associate professor at the University of Pennsylvania, where he leads the Machine Biology Group. When he was just a teenager trying to decide what to do with his life, César de la Fuente compiled a list of the world's biggest problems. He ranked them inversely by how much money governments were spending to solve them. Antimicrobial resistance topped the list. Twenty years on, the problem has not gone away.

One in six laboratory-confirmed bacteria tested in 2023 proved resistant to antibiotic treatment, according to the World Health Organization. All were related to various common diseases. The proliferation of difficult-to-treat bacterial diseases represents a growing threat, according to the World Health Organization's (WHO) Global Antibiotic Resistance Surveillance Report. The report reveals that, between 2018 and 2023, antibiotic resistance increased by more than 40 percent in monitored pathogen-drug combinations, with an average annual increase of 5-15 percent. According to data reported by more than 100 countries to WHO's Global Antimicrobial Resistance and Use Surveillance System (GLASS), one in six laboratory-confirmed bacteria in 2023 proved resistant to antibiotic treatment, all related to various common diseases globally.

In this era of AI slop, the idea that generative AI tools like Midjourney and Runway could be used to make art can seem absurd. But amid all the muck, there are people using AI tools with real consideration and intent. Some of them are finding notable success as AI artists: They are gaining huge online followings, selling their work at auction, and even having it exhibited in galleries and museums. This story is from our forthcoming print issue, which is all about the body. Plus, you'll also receive a free digital report on nuclear power. Take our quiz: How much do you know about antimicrobial resistance?

Take our quiz: How much do you know about antimicrobial resistance? A growing number of infections are proving impervious to antibiotics. This week we had some terrifying news from the World Health Organization: Antibiotics are failing us. A growing number of bacterial infections aren't responding to these medicines--including common ones that affect the blood, gut, and urinary tract. Get infected with one of these bugs, and there's a fair chance antibiotics won't help. The scary truth is that a growing number of harmful bacteria and fungi are becoming resistant to drugs.

Antimicrobial resistance (AMR) poses a significant public health and economic challenge, increasing treatment costs and reducing antibiotic effectiveness. This study employs machine learning to analyze genomic and epidemiological data from the public databases for molecular typing and microbial genome diversity (PubMLST), incorporating data from UK government-supported AMR surveillance by the Food Standards Agency and Food Standards Scotland. We identify AMR patterns in Campylobacter jejuni and Campylobacter coli isolates collected in the UK from 2001 to 2017. The research integrates whole-genome sequencing (WGS) data, epidemiological metadata, and economic projections to identify key resistance determinants and forecast future resistance trends and healthcare costs. We investigate gyrA mutations for fluoroquinolone resistance and the tet(O) gene for tetracycline resistance, training a Random Forest model validated with bootstrap resampling (1,000 samples, 95% confidence intervals), achieving 74% accuracy in predicting AMR phenotypes. Time-series forecasting models (SARIMA, SIR, and Prophet) predict a rise in campylobacteriosis cases, potentially exceeding 130 cases per 100,000 people by 2050, with an economic burden projected to surpass 1.9 billion GBP annually if left unchecked. An enhanced Random Forest system, analyzing 6,683 isolates, refines predictions by incorporating temporal patterns, uncertainty estimation, and resistance trend modeling, indicating sustained high beta-lactam resistance, increasing fluoroquinolone resistance, and fluctuating tetracycline resistance.

The Antibiotic Resistance Microbiology Dataset (ARMD) is a de-identified resource derived from electronic health records (EHR) that facilitates research into antimicrobial resistance (AMR). ARMD encompasses data from adult patients, focusing on microbiological cultures, antibiotic susceptibilities, and associated clinical and demographic features. Key attributes include organism identification, susceptibility patterns for 55 antibiotics, implied susceptibility rules, and de-identified patient information. This dataset supports studies on antimicrobial stewardship, causal inference, and clinical decision-making. ARMD is designed to be reusable and interoperable, promoting collaboration and innovation in combating AMR. This paper describes the dataset's acquisition, structure, and utility while detailing its de-identification process.

Antibiotics are often grouped by their mechanisms of action, such as blocking protein synthesis, disrupting folate biosynthesis, changing cell wall construction, compromising the cell membrane integrity and affecting DNA replication [93, 25]. These antibiotics, whether created in labs or found in nature, serve as the primary defence against bacterial infections. However, bacteria employ a series of strategies in response to resist these antibiotics, including inactivating antibiotics through enzymatic degradation, altering the antibiotic target, modifying cell membrane permeability, and using efflux pumps to maintain intracellular antibiotic concentrations of antibiotics below inhibitory levels [25]. Moreover, the gene transfer of antibiotic-resistant bacteria (ARB) further aggravates this challenge [92].

Artificial intelligence (AI) assisting with antimicrobial prescribing raises significant moral questions. Utilising ethical frameworks alongside AI-driven systems, while considering infection specific complexities, can support moral decision making to tackle antimicrobial resistance.

Antimicrobial resistance (AMR) is a growing public health threat, estimated to cause over 10 million deaths per year and cost the global economy 100 trillion USD by 2050 under status quo projections. These losses would mainly result from an increase in the morbidity and mortality from treatment failure, AMR infections during medical procedures, and a loss of quality of life attributed to AMR. Numerous interventions have been proposed to control the development of AMR and mitigate the risks posed by its spread. This paper reviews key aspects of bacterial AMR management and control which make essential use of data technologies such as artificial intelligence, machine learning, and mathematical and statistical modelling, fields that have seen rapid developments in this century. Although data technologies have become an integral part of biomedical research, their impact on AMR management has remained modest. We outline the use of data technologies to combat AMR, detailing recent advancements in four complementary categories: surveillance, prevention, diagnosis, and treatment. We provide an overview on current AMR control approaches using data technologies within biomedical research, clinical practice, and in the "One Health" context. We discuss the potential impact and challenges wider implementation of data technologies is facing in high-income as well as in low- and middle-income countries, and recommend concrete actions needed to allow these technologies to be more readily integrated within the healthcare and public health sectors.

Long diagnostic wait times hinder international efforts to address antibiotic resistance in M. tuberculosis. Pathogen whole genome sequencing, coupled with statistical and machine learning models, offers a promising solution. However, generalizability and clinical adoption have been limited by a lack of interpretability, especially in deep learning methods. Here, we present two deep convolutional neural networks that predict antibiotic resistance phenotypes of M. tuberculosis isolates: a multi-drug CNN (MD-CNN), that predicts resistance to 13 antibiotics based on 18 genomic loci, with AUCs 82.6-99.5% and higher sensitivity than state-of-the-art methods; and a set of 13 single-drug CNNs (SD-CNN) with AUCs 80.1-97.1% and higher specificity than the previous state-of-the-art. Using saliency methods to evaluate the contribution of input sequence features to the SD-CNN predictions, we identify 18 sites in the genome not previously associated with resistance. The CNN models permit functional variant discovery, biologically meaningful interpretation, and clinical applicability. Pathogen whole genome sequencing, coupled with statistical and machine learning models, offers a promising solution to multi-drug resistance diagnosis. Here, the authors present two deep convolutional neural networks that predict the antibiotic resistance phenotypes of M. tuberculosis isolates.